Innova Captab's Q3 FY26: Stellar Growth and Strategic Expansion

Innova Captab Limited, a prominent pharmaceutical player, recently unveiled its financial results for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The company reported a stellar performance, marked by robust revenue growth and strategic advancements across its key business segments. This quarter's results underscore Innova Captab's disciplined execution, comprehensive product pipeline, and unwavering operational focus in a dynamic market.

For Q3 FY26, Innova Captab's revenue from operations surged by an impressive 42% year-on-year, reaching ₹450.3 crores. The nine-month period also demonstrated strong momentum, with revenue hitting ₹1,182.2 crores, a 27% increase year-on-year. This growth was not just about numbers; it reflected enhanced client engagement in the CDMO business and strategic geographic expansion in the branded generics vertical, supported by robust output from all manufacturing facilities. Profitability also advanced, with EBITDA climbing to ₹71.1 crores in Q3 FY26, a 40% YoY increase, and ₹183.7 crores for 9M FY26, up 25%. The EBITDA margin remained steady at 15.8% for the quarter and 15.5% for the nine months, reflecting disciplined cost management. Profit After Tax (PAT) stood at ₹42.1 crores for Q3 FY26, a 23% YoY growth, and ₹102.8 crores for 9M FY26.

Segmental Performance and Strategic Drivers

Innova Captab's growth story in Q3 FY26 was significantly propelled by its two core business areas: CDMO Services and Products, and Branded Generics. The CDMO segment delivered a strong 29% year-on-year growth in Q3 FY26, contributing ₹298.7 crores to the total revenue. This performance was a result of deeper client engagement and continuous enhancement of the company's product portfolio. For the nine-month period, CDMO operations grew by 18% year-on-year, reaching ₹813.9 crores.

The Branded Generics business showcased even more remarkable growth, clocking a sharp 79% year-on-year increase in Q3 FY26 to ₹151.6 crores. Over the nine months, this segment grew by 56% year-on-year, achieving ₹368.4 crores. This surge was primarily driven by aggressive geographic expansion, both domestically and internationally, coupled with intensified penetration in established markets. The company's international presence is also expanding, with exports contributing a healthy 35% to the overall revenue mix in Q3 FY26 and 32% in 9M FY26, up from 25-27% in Q3 FY25.

Financial Summary (Consolidated)

Strategic Initiatives and Future Outlook

A significant highlight for Innova Captab is the commercialization and ramp-up of its state-of-the-art manufacturing facility in Kathua, Jammu. This facility, which commenced commercial operations in January 2025, contributed approximately ₹89 crores in revenue in Q3 FY26. Management expects the Jammu plant to achieve ₹270-280 crores in revenue for FY26 and has the potential to reach over ₹1,400 crores at optimum capacity (65%-75%). The plant is also strategically positioned to benefit from government incentives under the 'New Central Sector Scheme,' including GST-linked incentives and capital interest subvention.

The company has also bolstered its capabilities with prestigious GMP certifications, including UK-MHRA approval for its cephalosporin Baddi unit and PIC/S via SMDC Ukraine for all Jammu blocks. These certifications are crucial for expanding reach into regulated, high-growth international markets, reinforcing Innova Captab's adherence to global quality standards. The management reiterated an overall growth guidance of 20% plus year-on-year for FY27 and expects EBITDA margins to be maintained around 15% (+/- 2%).

Research and Development Focus

Innova Captab continues to prioritize Research and Development (R&D) as a core strength. The company operates a dedicated R&D facility in Baddi, recognized by the Department of Scientific and Industrial Research (DSIR). This facility is equipped with comprehensive tools for developing solid oral and liquid dosage forms, including advanced instruments like HPLC and UV dissolution apparatuses. The R&D efforts are focused on developing products in categories such as immediate release, super bioavailability capsules, nano size formulations, and modified and sustained releases, ensuring a continuous pipeline of innovative product offerings.

Conclusion: Powering Potential with Disciplined Execution

Innova Captab's Q3 and 9M FY26 performance reflects a company excelling with passion and powering its potential through disciplined execution and strategic foresight. The robust growth in both CDMO and Branded Generics, coupled with the successful ramp-up of the Jammu facility and strategic global certifications, positions Innova Captab for sustained growth. While challenges such as API price volatility and increasing competition exist, the management's proactive approach, focus on R&D, and commitment to operational excellence are key to unlocking greater stakeholder value in the long term. The company's strategic initiatives are delivering tangible results, reinforcing its competitive edge and operational resilience, ensuring consistent, high-quality growth through FY26 and beyond.